Authors [reference] | Year | Country | Subjects (intervention/ control) |
Age (years) (intervention/ control) |
Surgery type |
Intervention (somatostatin analog) |
Control | Published or unpublished |
---|---|---|---|---|---|---|---|---|
Carcoforo (17) | 2003 | Italy | 125/136 | 63/63 | Mastectomy | Octreotide | Standard treatment | Published |
Mahmoud (18) | 2007 | Egypt | 30/20 | 47/49 | Mastectomy | Octreotide | Standard treatment | Published |
Chemi SpA (19) | 2012 | Italy | 86/28 | 56/54 | Mastectomy | Octreotide | Placebo | Unpublished |
Gauthier (20) | 2012 | France | 72/73 | 56/59 | Mastectomy | Lanreotide | Placebo | Published |
Chéreau (21) | 2016 | France | 42/48 | 55/52 | Mastectomy | Pasireotide | Placebo | Unpublished |
Chemi SpA (22) | 2020 | Italy | 24/24 | NR/NR | Mastectomy | Octreotide | Placebo | Published |
Prajapati (23) | 2021 | India | 15/15 | 48/45 | Mastectomy | Octreotide | Standard treatment | Published |
Authors [reference] |
Risk of bias 2 tool assessment | |||||
---|---|---|---|---|---|---|
Bias arising from the randomization process |
Bias due to deviations from intended interventions |
Bias due to missing outcome data |
Bias in the measurement of the outcome |
Bias in the selection of the reported results |
Overall risk of bias |
|
Carcoforo (17) | Some concerns | Low | Low | Low | Some concerns | Some concerns |
Mahmoud (18) | Some concerns | Low | Low | Some concerns | Some concerns | Some concerns |
Gauthier (20) | Some concerns | Low | Low | Low | Some concerns | Some concerns |
Chéreau (21) | Low | Low | Low | Low | Low | Low |
Prajapati (23) | Low | Low | Low | Low | Low | Low |
The efficacy and safety of somatostatin analog after axillary node dissection | ||||||
---|---|---|---|---|---|---|
Patient or population: Adults with breast cancer with axillary lymph node metastasis; Setting: Inpatients; Intervention: Somatostatin analog; Comparison: Placebo or standard treatment |
||||||
Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | Patients (studies) | Certainty of the evidence (GRADE) | Comments | |
Risk with control | Risk with somatostatin analog | |||||
Drained fluid volume | Median volume of drained fluid = 145 mL | MD −22.1 mL (−42.1 to −2.1) | - | 576 (5 RCTs) | Lowa,b | Somatostatin analog reduced the drained fluid volume |
Drainage duration | Median duration of drainage = 4.5 days | MD −0.48 days (−1.43 to 0.46) | - | 685 (6 RCTs) | Lowa,b | Somatostatin analog resulted in little to no difference in the drainage duration |
Seroma | 459 per 1000 | 418 per 1000 (280 to 615) | RR 0.91 (0.61 to 1.34) | 311 (4 RCTs) | Lowa,b | Somatostatin analog resulted in little to no difference in seroma |
Hematoma | 8 per 1000 | 4 per 1000 (1 to 28) | RR 0.53 (0.08 to 3.53) | 253 (3 RCTs) | Lowb,c | Somatostatin analog resulted in little to no difference in hematoma |
Surgical site infection | 31 per 1000 | 19 per 1000 (8 to 44) | RR 0.62 (0.27 to 1.41) | 598 (5 RCTs) | Lowb,c | Somatostatin analog resulted in little to no difference in surgical site infection |
Length of hospitalization | Median length of hospitalization = 5 days | MD −0.79 SD (−1.30 to −0.27) | - | 526 (4 RCTs) | Lowa,b | Somatostatin analog reduced the length of hospitalization |